What’s the current market cap for BrainsWay stock?

BrainsWay (BWAY) has a market cap of $635m as of July 04, 2026.

What is the P/E ratio for BrainsWay stock?

The price to earnings (P/E) ratio for BrainsWay (BWAY) stock is 69.3 as of July 04, 2026.

Does BrainsWay stock pay dividends?

No, BrainsWay (BWAY) stock does not pay dividends to its shareholders as of July 04, 2026.

When is the next BrainsWay dividend payment date?

BrainsWay (BWAY) stock does not pay dividends to its shareholders.

What is the beta indicator for BrainsWay?

BrainsWay (BWAY) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy BrainsWay stock | $BWAY Share Price

13:30

15:10

16:45

18:25

20:00

About BrainsWay

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Ticker

$BWAY

Sector

Health

Primary listing

NASDAQ

Employees

129

Headquarters

Jerusalem, Israel

Website

www.brainsway.com

BrainsWay Metrics

BasicAdvanced

$635m

69.30

$0.22

0.15

Bulls say / Bears say

Q1 2026 revenue rose 35% year-over-year to $15.5 million, with net income more than doubling to $2.3 million and adjusted EBITDA up 117%, demonstrating meaningful operating leverage. (Reuters)

Remaining performance obligations grew 25% to approximately $75 million as of March 31, 2026, reflecting expanding contracted revenue visibility and a strong backlog. (Form 6-K)

A multicenter randomized study showed BrainsWay’s accelerated Deep TMS protocol achieved comparable remission and response rates to the standard protocol with no serious adverse events, supporting its clinical differentiation and market potential. (Reuters)

Full-year 2026 revenue guidance of $66 million to $68 million, with the midpoint of $67 million only marginally above the $66.43 million analyst consensus, suggests limited upside to current estimates. (Investing.com)

Despite 35% year-over-year growth, absolute Q1 2026 revenue of $15.5 million remains modest, underscoring the company’s limited scale and raising questions about the path to sustainable profitability. (Form 6-K)

BrainsWay committed over $11 million to convertible loans and minority investments in Neurolief, BrainStim Health, and Axis Management, which may strain capital allocation and divert resources from core Deep TMS commercialization. (Form 6-K)

Data summarised monthly by Lightyear AI. Last updated on 1 Jul 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

Q1 2026 revenue rose 35% year-over-year to $15.5 million, with net income more than doubling to $2.3 million and adjusted EBITDA up 117%, demonstrating meaningful operating leverage. (Reuters)

Remaining performance obligations grew 25% to approximately $75 million as of March 31, 2026, reflecting expanding contracted revenue visibility and a strong backlog. (Form 6-K)

Data summarised monthly by Lightyear AI. Last updated on 1 Jul 2026.